Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 384-391

  Fitzpatrick, Annette L ^a   Irizarry, Michael C ^b   Cushman, Mary ^c   Jenny, Nancy S ^c   Chi, Gloria C ^a   Koro, Carol ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cardiovascular risk factors; Dementia; Lp PLA2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E; THROMBOCYTE ACTIVATING FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMMUNITY LIVING; DEMENTIA; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; RISK; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ALZHEIMER DISEASE; DEMENTIA; FEMALE; HUMANS; MALE; RISK; RISK FACTORS;

EID: 84917686584     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.032     Document Type: Article

References (39)

1. Asano K., Okamoto S., Fukunaga K., Shiomi T., Mori T., Iwata M., et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999, 261:511-514.
2. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000, 150:413-419.
3. MacPhee C.H., Moores K.E., Boyd H.F., Dhanak D., Ife R., Leach C., et al. Lipoprotein associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999, 338:479-487.
4. Tselepis A.D., Chapman M.J. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis 2002, (Suppl.3):57-68.
5. Packard C.J., O'Reilly D.S., Caslake M.J., McMahon A.D., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. NEngl J Med 2000, 343:1148-1155.
6. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
7. Caslake M.J., Packard C.J. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003, 14:347-352.
8. Rader D.J. Inflammatory markers of coronary risk. NEngl J Med 2000, 343:1179-1182.
9. Oei H.H., van der Meer I.M., Hofman A., Koudstaal P.J., Stijnen T., Breteler M.M., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
10. 2 Studies Collaboration.
11. Anstey K.J., Lipnicki D.M., Low L.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatric Psychiatry 2008, 16(5).
12. Kennelly S.P., Lawlor B.A., Kenny R.A. Blood pressure and the risk for dementia-A double edged sword. Ageing Res Rev 2009 April, 8(2):61-70.
13. Van Oijen M., van der Mer I.M., Hofman A., Witteman J.C.M., Koudstaal P.J., Breteler M.M.B. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol 2006, 59:139-144.
14. van Himbergen T.M., Beiser A.S., Ai M., Seshadri S., Otokozawa S., Au R., et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Arch Neurol 2012, 69:594-600.
15. Fried L.P., Borhani N.O., Enright P., Furberg C.D., Gardin J.M., Kronmal R.A., et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991, 1:263-276.
16. Tell G.S., Fried L.P., Hermanson B., Manolio T.A., Newman A.B., Borhani N.O. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993, 3:358-366.
17. Lopez O.L., Kuller L.H., Fitzpatrick A.L., Ives D., Becker J.T., Beauchamp N. Evaluations of dementia in the cardiovascular health cognition study. Neuroepidemiology 2003, 22:1-12.
18. Fitzpatrick A.L., Kuller L.H., Ives D., Lopez O.L., Jagust W., Breitner J., et al. Incidence and prevalence of dementia in the cardiovascular health study. JAm Geriatr Soc 2004, 52:195-204.
19. APA: DSM-IV Diagnostic and statistic manual of mental disorders 1994, American Psychiatric Association, Washington, D.C. 4th ed.
20. McKhann G., Drachman D.A., Folstein M.F., Katzman R., Price D.L., Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
21. Chui H.C., Victoroff J.I., Margolin D., Jagust W., Shankle R., Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992, 42:473-480.
22. Suzuki T., Solomon C., Jenny N.S., Tracy R., Nelson J.J., Psaty B.M., et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. Sep 2009, 2(5):429-436.
23. Wahl P.W., Savage P.J., Psaty B.M., Orfanrd T.J., Robbins J.A., Tracy R.P. Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet 1998, 352:1012-1015.
24. Psaty B.M., Kuller L.H., Bild D., Burke G.L., Kittner S.J., Mittelmark M., et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995, 5:270-277.
25. Ives D.G., Fitzpatrick A.L., Bild D.E., Psaty B.M., Kuller L.H., Crowley P.M., et al. Surveillance and ascertainment of cardiovascular events. Ann Epidemiol 1995, 5:278-285.
26. Psaty B.M., Lee M., Savage P.J., Rutan G.H., German P.S., Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. JClin Epidemiol 1992 Jun, 45(6):683-692.
27. O'Leary D.H., Polak J.F., Wolfson S.K., Bond M.G., Bommer W., Sheth S., et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study CHS Collaborative Research Group. Stroke 1991, 22:1155-1163.
28. Newman A.B., Siscovick D.S., Manolio T.A., Polak J., Fried L.P., Borhani N.O., et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993, 88:837-845.
29. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995, 41:264-270.
30. Jenny N.S., Yanez N.D., Psaty B.M., Kuller L.H., Hirsch C.H., Tracy R.P. Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007, 165:684-695.
31. Furberg C.D., Nelson J.J., Solomon C., Cushman M., Jenny N.S., Psaty B.M. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. JAm Geriatr Soc 2008 May, 56(5):792-799.
32. Jenny N.S., Solomon C., Cushman M., Tracy R.P., Nelson J.J., Psaty B.M., et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 2010, 209:528-532.
33. Rubenstein A., Izkhakov E. Lipoprotein associated phospholipase A2. Harefuah 2011, 150:136-140.
34. Corson M.A., Jones P.H., Davidson M.H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008, 101(Suppl.):41F-50F.
35. Dadu R.T., Nambi V., Ballantyne C.M. Developing and assessing cardiovascular biomarkers. Transl Res 2012, 1-13. [e-copy prior to publication].
36. 2 and cerebral microbleeds in the Framingham Heart Study. Stroke 2012 Nov, 43(11):3091-3094. 10.1161/STROKEAHA.112.656744.
37. Drenos F., Talmud P.J., Casas J.P., Smeeth L., Palmen J., Humphries S.E., et al. Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet 2009, 18:2305-2316.
38. 2 activity and mass in the Framingham Heart Study. PLoS Genet 2010, 6:e1000928. 10.1371/journal.pgen.1000928.
39. Koshy B., Miyashita A., St Jean P., Stirnadel H., Kaise T., Rubio J.P., et al. Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan. JAlzheimers Dis 2010, 21:775-780.